NCT04310020 2026-03-17
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT07358676 2026-01-22
A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06379087 2025-07-10
Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT00983307 2025-04-30
A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer
Thomas Jefferson University
Phase 2 Completed
NCT05443646 2024-05-07
Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05161533 2023-10-18
Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial
University of Washington
Phase 2 Withdrawn
NCT04372927 2023-06-13
ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
University of Washington
Phase 2 Terminated
NCT03663764 2021-12-10
Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor
Sun Yat-sen University
Phase 2 Unknown
NCT02701400 2021-06-22
Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer
Emory University
Phase 2 Completed
NCT04543890 2020-09-10
CTV
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT02947113 2017-11-30
HYPOLAN
The Netherlands Cancer Institute
Phase 2 Withdrawn